Search

Esmolol

Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. … It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions.

Bendamustine

It is active against both active and quiescent cells, although the exact mechanism of action is unknown. … Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules.

Edetate calcium disodium anhydrous

Edetate calcium disodium is a metal ion chelator used to reduce blood concentrations and depot stores of lead from the body. … [L12774] It is on the World Health Organization Model List of Essential Medicines.[A204173] Edetate calcium disodium was granted FDA approval on 16 July 1953.[L12774]

Imiglucerase

The modification alters the sugar residues at the non-reducing ends of the oligosaccharide chains of the glycoprotein so that they are predominantly terminated with mannose residues. … Alglucerase is prepared by modification of the oligosaccharide chains of human Beta-glucocerebrosidase.

Lavender oil

Isoprenaline

Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion … [A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction

Enasidenib

Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow. … Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2)

Vilobelimab

Vilobelimab is a chimeric monoclonal immunoglobulin G4 (IgG4) antibody that binds to the soluble form of human C5a with high affinity. … The drug is not yet fully approved for this condition.[L45849]

Anti-inhibitor coagulant complex

It is used to control bleeding in hemophilia A and B patients with inhibitors. … Anti-inhibitor coagulant complex, also known as FEIBA (factor eight inhibitor bypassing activity), contains several proteins involved in the prothrombinase complex.